17,261 trials
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) at Week 12 — -1.07; -1.09; -1.44; -1.33 percentage of HbA1c — p=0.459
Posttraumatic Stress Disorder · Alcohol Use Disorders
Primary: Clinician Administered PTSD Scale — 34.2; 32.5 score on a scale
Mitochondrial Disease · Neurology · Myopathy
Primary: Newcastle Paediatric Mitochondrial Disease Scale (NPMDS) Part I-III, Baseline — 23.9; 20.4 Units on a scale
Endocrine Disease · Diabetes
Primary: Change in Insulin Sensitivity Index — 1.49; 1.41 min-1·μU·ml-1 — p=0.60
Cystic Fibrosis
Primary: Change From Baseline in Sputum Bacterial Load — -2.1; -1.03; -1.28; -1.7 log 10 cfu/ml
Actinic Keratosis
Primary: Percentage of Participants With Complete Response of Actinic Keratosis — 43; 32 percentage of participants
Liver Cancer
Primary: Overall Image Quality of Magnetic Resonance Elastography (MRE)
Respiratory Syncytial Viruses
Primary: Area Under the Viral Load-time Curve (VL-AUC) — 19.94; 14.74; 16.44; 15.33 log10 copies-/ml*days — p=0.808
Esophageal Cancer
Primary: Pathologic Complete Response (PCR) Rate
Kidney Cancer
Primary: Proportion of Patients With Response — 0.18; 0.11 proportion of participants
HER2-Positive Breast Carcinoma · Invasive Breast Carcinoma · Metastatic Malignant Neoplasm in the Brain
Primary: Complete Response (CR) Rate in the Brain at 12 Weeks Post-radiation Therapy (RT) Using the RECIST 1.1 Criteria Based on Brain Magnetic Resonance Imaging (MRI) — 5.8; 0…
Respiratory Syncytial Virus Infections
Primary: Percentage of Participants With Asthma After Respiratory Syncytial Virus (RSV) Infection — 0; 0; 0 percentage of participants
Barrett's Esophagus
Primary: Change in Ki67 Biomarker Expression — 1539; 1556; 1575; 1864 cells/mm^2
Well-differentiated Non-functional NET of Thoracic Origin · Well-differentiated Non-functional NET of Gastrointestinal Origin · Well-differentiated Non-functional NET of Pancreatic Origin
Primary: Overall Response Rate (ORR) by RECIST 1.1 and as Per Blinded Independent Central Review (BIRC). — 7.4; 4.8 Percentage of participants
Schizophrenia
Primary: Number of Participants With Adverse Event and Adverse Drug Reaction — 9; 9; 11; 5 Participants